Precipio's Omnia Methodology Enables Diagnosis Of MDS With Peripheral Blood Instead Of Bone Marrow Biopsy
Portfolio Pulse from Benzinga Newsdesk
Precipio's Omnia methodology enables diagnosis of myelodysplastic syndrome (MDS) using peripheral blood instead of bone marrow biopsy. The HemeScreen Cytopenia panel allowed for molecular identification of driver mutations, providing a comprehensive and rapid result for clinicians to act upon.
June 14, 2023 | 1:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Precipio's Omnia methodology offers a less invasive and faster diagnostic process for MDS, potentially increasing demand for the company's HemeScreen Cytopenia panel.
The Omnia methodology allows for a more comprehensive and rapid diagnosis of MDS using peripheral blood instead of bone marrow biopsy. This less invasive and faster process could lead to increased demand for Precipio's HemeScreen Cytopenia panel, positively impacting the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100